BSXBy Calypso Research7 min read

Boston Scientific Corporation (BSX) Q4 2025 Earnings Analysis

Defibrillating Expectations as BSX Shocks with 15.9% Growth

Key Takeaways

Boston Scientific Corporation (BSX) reported Q4 2025 earnings with revenue of $5.3B, representing a +15.9% year-over-year change. The stock moved -17.6% on earnings day.

The bull case: Broad-based portfolio strength, sustained EP/WATCHMAN leadership, and incremental upside from CHAMPION and Penumbra enable Boston Scientific to compound double-digit revenue and EPS growth through 2028 with expanding margins.

The bear case: EP market growth normalizes faster than expected, WATCHMAN underdelivers on CHAMPION-driven expansion, and integration/execution risks around MedSurg and Penumbra prevent Boston Scientific from achieving its 10%+ long-range growth and margin expansion targets.

Financial Highlights

  • Revenue: $5.3B (+15.9% YoY)
  • Gross Profit: $3.9B (74.5% margin, +15.9% YoY)
  • Operating Income: $1.2B (22.8% margin, +9.9% YoY)
  • Net Income: $668M
  • TTM Revenue: $20.1B

Stock Performance

  • Earnings Day Move: -17.6%
  • Year-to-Date: -21.5%
  • 1-Year Return: -28.8%
  • vs. S&P 500 (since earnings): -26.1%
  • vs. Nasdaq (since earnings): -22.8%

View live BSX data, AI chat, and interactive debates on Calypso →

What Management Said

Here are the key debates and direct quotes from Boston Scientific Corporation's Q4 2025 earnings call:

Sustainability of EP (PFA) Growth and Market Share as Competitors Launch

Sentiment: Positive

"Specific to EP, really pleased with the results at 35%... we think the market in Q4 was closer to 18% to 20% growth rather than with some other companies that claim to 25%... we’ve called the market for 2026, about 15% growth." — Mike Mahoney
"We did anticipate that. And we are also very comfortable to say, as we looked at the end of '26 that we'll be the clear EFA market leader... and we also think our EP business [will] grow faster than 15%." — Mike Mahoney

WATCHMAN Durability and CHAMPION Trial Implications (Including Concomitant Procedures)

Sentiment: Positive

"With WATCHMAN, we grew 29%... we pretty much are the market with WATCHMAN... we did annualize the concomitant reimbursement... so we're quite proud of the 29%." — Mike Mahoney
"There are 2 co-primary endpoints: one, noninferiority for combined endpoint stroke systemic embolism and [indiscernible]. One for bleeding... the bleeding endpoint is powered as a superiority endpoint... a positive CHAMPION would give increased [indiscernible] to referring for the current indication, which includes the option indication." — Ken Stein

Near-Term Growth Cadence and 2026 Guide vs Street Expectations (Q1 Softness, ACURATE & AXIOS Headwinds)

Sentiment: Positive

"We expect first quarter 2026... operational and organic revenue growth to be in a range of 8.5% to 10%, which includes an approximate 150 basis point impact from the discontinuation of ACURATE and a transient impact associated with the product removal of certain sizes of our AXIOS device." — Jonathan Monson
"We guided full year to 10% to 11%, which we think is strong guidance... [Q1] 8.5% to 10% [is] simply 2 factors really. One is our toughest comp of the year. And secondly, we do have the about 150 bps of impact from the ACURATE discontinuation along with the Axios... withdrawal... which will impact the first half of the year." — Mike Mahoney

Breadth and Reliability of Diversified Growth Drivers Beyond EP and WATCHMAN

Sentiment: Positive

"We do expect our PI business, our euro business, our [neuromod] business and our CRM businesses to have stronger years in '26 than they did in '25... Not many questions on [neuromod], but that business we expect to be a high performer in '26, along with improvement in PI, euro and CRM." — Mike Mahoney
"We continue to diversify and strengthen the ICTX business... our complex coronary business grew 31% in the quarter, 23% for the year... our IO business has now scaled to over $1 billion, growing nicely in the double digits... it's the entire company that gives us confidence in the 10% to 11% guide for the full year." — Mike Mahoney

Long-Term LRP Credibility and Impact of Penumbra on Growth and Margins

Sentiment: Positive

"If we were doing our Investor Day today, we'd get the same numbers. 10% plus '26 to '28, 150 bps of margin improvement, strong double [indiscernible] growth even within that. And then we think Penumbra further enhances our WAMGR and further strengthens the company beyond that." — Mike Mahoney
"We expect full year 2026 adjusted earnings per share to be in a range of $3.43 to $3.49, representing growth of 12% to 14% versus 2025... we expect to expand adjusted operating margin by 50 to 75 basis points progressing toward our goal of 150 basis points of operating margin expansion over our long-range plan." — Jonathan Monson

Bull Case

Broad-based portfolio strength, sustained EP/WATCHMAN leadership, and incremental upside from CHAMPION and Penumbra enable Boston Scientific to compound double-digit revenue and EPS growth through 2028 with expanding margins.

Bear Case

EP market growth normalizes faster than expected, WATCHMAN underdelivers on CHAMPION-driven expansion, and integration/execution risks around MedSurg and Penumbra prevent Boston Scientific from achieving its 10%+ long-range growth and margin expansion targets.

Looking Ahead

With revenue growing +15.9% year-over-year, the key question is whether Boston Scientific Corporation can sustain this growth trajectory, particularly around sustainability of EP (PFA) Growth and Market Share as Competitors Launch. With operating margins at 22.8%, margin trends will remain a focal point. The market's negative earnings-day reaction signals that investors need to see stronger execution, and the next earnings report will be a key catalyst for the stock.

Frequently Asked Questions

What was Boston Scientific Corporation's revenue in Q4 2025?

Boston Scientific Corporation reported Q4 2025 revenue of $5.3B, representing a +15.9% year-over-year change.

Did Boston Scientific Corporation beat earnings expectations in Q4 2025?

The stock declined -17.6% on earnings day, suggesting the results fell short of market expectations. The current bull case centers on: Broad-based portfolio strength, sustained EP/WATCHMAN leadership, and incremental upside from CHAMPION and Penumbra enable Boston Scientific to compound double-digit revenue and EPS growth through 2028 with expanding margins.

What is the bull case for BSX stock?

The bull case for BSX centers on: Broad-based portfolio strength, sustained EP/WATCHMAN leadership, and incremental upside from CHAMPION and Penumbra enable Boston Scientific to compound double-digit revenue and EPS growth through 2028 with expanding margins.

What is the bear case for BSX stock?

The bear case for BSX centers on: EP market growth normalizes faster than expected, WATCHMAN underdelivers on CHAMPION-driven expansion, and integration/execution risks around MedSurg and Penumbra prevent Boston Scientific from achieving its 10%+ long-range growth and margin expansion targets.

How has BSX stock performed since its Q4 2025 earnings?

BSX moved -17.6% on the day of its Q4 2025 earnings report, underperforming the S&P 500 by +26.1% since earnings. Year-to-date, the stock has returned -21.5%.

Browse all 400+ earnings reports →

Learn More

Analyze BSX in Real Time

This is a static snapshot. For live financial data, AI-powered chat, and interactive earnings debates for Boston Scientific Corporation and 400+ other stocks, explore the full platform.

Open BSX on Calypso →

Calypso is an AI-powered equity research platform used by investment teams to cut earnings research time by over 80%.